Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the announcement as ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

Royal Bank of Canada restated their outperform rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report published ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the ...